07:00 , Jun 27, 2016 |  BC Week In Review  |  Company News

Teva, Sagent Pharmaceuticals deal

Teva will sell five U.S. ANDAs, including anesthetic drug Propofol Injectable Emulsion 1%, to Sagent for $40 million. Teva declined to disclose further details, and Sagent did not respond to inquiries. Last summer, Teva said...
07:00 , Jun 20, 2016 |  BC Week In Review  |  Company News

AstraZeneca, Aspen deal

AstraZeneca granted Aspen exclusive rights to commercialize AZ’s anesthetics portfolio outside the U.S. The portfolio consists of seven drugs, including general anesthetic Diprivan propofol. AZ will manufacture and supply the products for 10 years. The...
07:00 , Apr 25, 2016 |  BioCentury  |  Politics, Policy & Law

SCOTUS to the rescue?

The U.S. Supreme Court will hear arguments on Monday in a case that could either overturn or reinforce policies that unfairly tilt the inter partes review system against patent holders, according to life sciences companies....
07:00 , Oct 5, 2015 |  BC Week In Review  |  Company News

BioQuiddity, Lee’s Pharmaceutical Holdings Ltd. deal

BioQuiddity granted Lee’s Pharmaceutical rights to commercialize ropivacaine and propofol infusion products in Taiwan and China, including Hong Kong and Macau. The products are single-use, unit-dose infusible products comprising the drug and a delivery system....
07:00 , Mar 23, 2015 |  BioCentury  |  Strategy

Show me the value

At a time when industry is struggling mightily with how to demonstrate the value of its products to payers and patients and translate that value into pricing, The Medicines Co. could provide some lessons. The...
07:00 , Sep 16, 2013 |  BioCentury  |  Emerging Company Profile

Tansna: Quieting convulsions

Propofol is used off-label in hospitals to treat uncontrolled seizures, but its potent sedative properties preclude everyday use. Tansna Therapeutics Inc. is developing non-sedating analogs of propofol that could help treat the one-third of epilepsy...
07:00 , Mar 18, 2013 |  BioCentury  |  Emerging Company Profile

gIcare: Colonoscopy comfort

gIcare pharma Inc. is developing a pipeline of non-sedating colonic analgesic compounds to provide new and lower cost alternatives for pain management during colonoscopy. Sedation during endoscopy has become routine practice among gastroenterologists, even though...
07:00 , Jul 23, 2012 |  BC Week In Review  |  Clinical News

Pelorus 1500 regulatory update

Sphere said it received CE Mark approval for its Pelorus 1500 point-of-care in vitro diagnostic to measure concentration of the IV anesthetic propofol in blood samples. Sphere plans to launch the product next year. Sphere...
07:00 , Jun 18, 2012 |  BC Week In Review  |  Clinical News

Dexdor dexmedetomidine regulatory update

The Scottish Medicines Consortium recommended the use of Dexdor dexmedetomidine from Orion on the National Health Service (NHS) in Scotland for sedation of adult intensive care unit (ICU) patients. The consortium said the selective adrenergic...
07:00 , Apr 26, 2010 |  BC Week In Review  |  Clinical News

Precedex dexmedetomidine: Phase III data

Top-line data from the double-blind, international Phase III PRODEX trial in 500 medical and surgical ICU patients requiring light to moderate sedation for mechanical ventilation showed that Precedex met the co-primary endpoint of providing similar...